>

Press Releases

YEAR
Date Description View
09/04/19

Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL151 for Parkinson's Disease and Launch of its Engage Parkinson's website

08/07/19

Denali Therapeutics Reports Second Quarter 2019 Financial Results and Business Highlights

08/05/19

Denali Therapeutics Announces that its Partner Sanofi has Commenced Dosing of DNL758 in a Phase 1 Study

06/11/19

Denali Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designation for DNL310, and Expands its Portfolio of Brain Penetrant Enzyme Replacement Programs

05/07/19

Denali Therapeutics Reports First Quarter 2019 Financial Results

03/12/19

Denali Therapeutics Reports Full Year 2018 Financial Results and Business Highlights

02/15/19

Denali Therapeutics Announces First Patient Dosed in Phase 1B Study of DNL747 for Alzheimer’s Disease

01/08/19

Denali Therapeutics Announces First Patient Dosed in Phase 1B Study of DNL747 for ALS

12/10/18

Denali Therapeutics Announces First Patient Dosed in Phase 1B Study of DNL201 for Parkinson's Disease

11/19/18

Denali Therapeutics Announces Positive Clinical Results With Its Lead RIPK1 Inhibitor Molecule and Intention to Initiate Patient Studies in Multiple Indications in Collaboration With Sanofi

Investors & Media Relations